Business Description
Hemab Therapeutics Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US4234941031
Description
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 152.04 | |||||
Equity-to-Asset | -0.91 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -9.39 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.35 | |||||
9-Day RSI | 51.19 | |||||
14-Day RSI | 55.71 | |||||
3-1 Month Momentum % | -8.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.03 | |||||
Quick Ratio | 18.03 | |||||
Cash Ratio | 17.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -43.92 | |||||
ROIC % | -1240.6 | |||||
ROC (Joel Greenblatt) % | -3285.8 | |||||
ROCE % | -51.24 | |||||
Moat Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -28.69 | |||||
EV-to-Forward-EBIT | -18.45 | |||||
EV-to-EBITDA | -28.82 | |||||
EV-to-Forward-EBITDA | -11.43 | |||||
EV-to-FCF | -32.72 | |||||
Earnings Yield (Greenblatt) % | -3.49 | |||||
FCF Yield % | -2.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COAG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hemab Therapeutics Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.33 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 55.71 | ||
| 14-Day ATR ($) | 4.225775 | ||
| 20-Day SMA ($) | 44.14925 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 23.0001 - 52.145 | ||
| Shares Outstanding (Mil) | 46.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hemab Therapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hemab Therapeutics Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hemab Therapeutics Holdings Inc Frequently Asked Questions
What is Hemab Therapeutics Holdings Inc(COAG)'s stock price today?
The current price of COAG is $46.56. The 52 week high of COAG is $52.15 and 52 week low is $23.00.
When is next earnings date of Hemab Therapeutics Holdings Inc(COAG)?
The next earnings date of Hemab Therapeutics Holdings Inc(COAG) is .
Does Hemab Therapeutics Holdings Inc(COAG) pay dividends? If so, how much?
Hemab Therapeutics Holdings Inc(COAG) does not pay dividend.
Guru Commentaries on NAS:COAG
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Hemab Therapeutics Holdings Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers